Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News


Suda Pharmaceutical's Prospectus



Prospectus for a renounceable pro rata offer to Eligible Shareholders of approximately 860,653,044 New Shares at an issue price of $0.004 per New Share on the basis of 1 New Share for every three Existing Shares held, together with one attaching Listed Option for every two New Shares issued, to raise up to approximately $3.4 million before issue costs. 

For more information, download the attached PDF.

 
Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?